$139.39 +0.06 (%) Pharmacyclics Inc - NASDAQ

Nov. 28, 2014 | 01:00 PM

Partner Headlines

  1. AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate Imbruvica In Hematologic Cancers

    Benzinga | Nov. 4, 2014 | 14:35PM EST
  2. Wainwright Sees TG Therapeutics As Take-Out Target

    Benzinga | Oct. 27, 2014 | 13:20PM EST
  3. Pharmacyclics Enters Into Agreement With Roche To Evaluate IMBRUVICA And GAZYVA In Lymphoma And Leukemia

    Benzinga | Oct. 16, 2014 | 14:47PM EST
  4. Pharmacyclics and Servier Agree To Conclude Pan-HDAC Inhibitor Collaboration

    Benzinga | Sep. 25, 2014 | 16:02PM EST
  5. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  6. UPDATE: Morgan Stanley Reiterates On Pharmacyclics, Inc. Following VA Contract News

    Benzinga | Sep. 11, 2014 | 09:53AM EST
  7. Pharmacyclics Price Target Cut On Higher Spending

    IBD | Sep. 8, 2014 | 13:02PM EST
  8. Infinity Pharma Joins AbbVie On Blood Cancer Drug

    IBD | Sep. 3, 2014 | 13:20PM EST
  9. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD | Aug. 26, 2014 | 14:38PM EST
  10. Target Expected To Be Right On Target With Earnings

    Benzinga | Aug. 20, 2014 | 07:13AM EST
  11. Pharmacyclics Appoints Chief Commercial Officer

    Benzinga | Aug. 18, 2014 | 16:05PM EST
  12. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD | Aug. 1, 2014 | 12:35PM EST
  13. Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics

    Benzinga | Jun. 30, 2014 | 09:18AM EST
  14. Pharmacyclics

    IBD | Jun. 9, 2014 | 18:41PM EST
  15. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga | May. 11, 2014 | 16:35PM EST
  16. AbbVie Beats Q1 Estimates, Downplays HCV 'Price War'

    IBD | Apr. 25, 2014 | 12:30PM EST
  17. Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite Aid Moves Higher

    Benzinga | Apr. 10, 2014 | 15:34PM EST
  18. Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva Drops

    Benzinga | Apr. 10, 2014 | 12:48PM EST
  19. Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

    Benzinga | Apr. 8, 2014 | 08:01AM EST
  20. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga | Mar. 27, 2014 | 15:57PM EST
  21. Morgan Stanley Starts Pharmacyclics With Equal-Weight; $120 PT -Reuters

    Benzinga | Mar. 26, 2014 | 16:27PM EST
  22. Celegene, Pharmacyclics Lead Biotech Short Interest Trend (CELG, MDVN, PCYC)

    Benzinga | Mar. 26, 2014 | 07:56AM EST
  23. Pharmacyclics target raised

    IBD | Mar. 20, 2014 | 18:47PM EST
  24. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD | Mar. 20, 2014 | 11:25AM EST
  25. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga | Mar. 19, 2014 | 13:31PM EST
  26. WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses

    IBD | Mar. 5, 2014 | 17:38PM EST
  27. Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

    GuruFocus | Mar. 3, 2014 | 09:31AM EST
  28. Pharmacyclics Hits High As Imbruvica Launches Big

    IBD | Feb. 21, 2014 | 12:31PM EST
  29. FDA Approvals And Changes For The Week Ending February 14, 2014

    Benzinga | Feb. 18, 2014 | 16:17PM EST
  30. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  31. Pharmacyclics up on FDA OK

    IBD | Feb. 12, 2014 | 18:43PM EST
  32. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD | Feb. 12, 2014 | 14:05PM EST
  33. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts | Jan. 22, 2014 | 09:25AM EST
  34. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts | Jan. 21, 2014 | 13:29PM EST
  35. ETF Outlook for Wednesday, January 8, 2014 (ROBO, PBE, SMH, EUFN)

    Benzinga | Jan. 8, 2014 | 07:31AM EST
  36. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD | Jan. 7, 2014 | 18:45PM EST
  37. Biotechs Jump On Drug News

    IBD | Jan. 7, 2014 | 18:40PM EST
  38. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD | Jan. 7, 2014 | 11:26AM EST
  39. The Top Five Drug Launches Of 2013

    IBD | Dec. 31, 2013 | 13:42PM EST
  40. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, GILD, PCYC)

    Benzinga | Dec. 26, 2013 | 13:26PM EST
  41. Qihoo, Noah Lead IBD 50's Top 5 Young Chinese Stocks

    IBD | Dec. 14, 2013 | 08:02AM EST
  42. Pharmacyclics Announces Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology

    Benzinga | Dec. 9, 2013 | 21:01PM EST
  43. Celgene, Infinity Rise On Blood Cancer Drug Data

    IBD | Dec. 9, 2013 | 11:24AM EST
  44. 2 Top Biotechs Presenting Data At Hematology Event

    IBD | Dec. 6, 2013 | 14:57PM EST
  45. 4 Potential Blockbuster Drugs Awaiting Launch

    IBD | Dec. 5, 2013 | 18:21PM EST
  46. SouFun, Zeltiq Lead IBD's Top 5 With Bolting RS Lines

    IBD | Dec. 3, 2013 | 08:02AM EST
  47. UPDATE: Piper Jaffray Initiates Coverage on Pharmacyclics as 2014 Biotech Sector Outlook Remains Strong

    Benzinga | Nov. 27, 2013 | 11:28AM EST
  48. Wedbush Reiterates on Pharmacyclics as IMBRUVICA Approved for Mantle Cell Lymphoma

    Benzinga | Nov. 14, 2013 | 10:54AM EST
  49. Market Wrap For November 13: Markets Await Janet Yellen's Big Day Thursday

    Benzinga | Nov. 13, 2013 | 16:49PM EST
  50. Pharmacyclics Drug Wins One Approval, Awaits Another

    IBD | Nov. 13, 2013 | 14:15PM EST
Trading Center